Welcome to our dedicated page for Pliant Therapeutics SEC filings (Ticker: PLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pliant Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing integrin-based therapeutics. Recent 8-K reports cover quarterly financial results, corporate updates for the PLN-101095 oncology program, material agreements, at-the-market equity offering arrangements, and amendments to the company’s stockholder rights agreement and Series A Junior Participating Preferred Purchase Rights.
Proxy and governance filings describe board composition, director retirements, committee roles, executive compensation, equity awards, and stockholder voting matters. Other material-event reports record officer appointments or departures and changes affecting security-holder rights, connecting the company’s capital structure and governance disclosures to its clinical-stage operating model.
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing integrin-based drugs, with a primary focus on oncology. Its wholly owned lead candidate, PLN-101095, is an oral dual inhibitor of αvβ8 and αvβ1 integrins for solid tumors resistant to immune checkpoint inhibitors.
In a Phase 1 open-label dose-escalation trial, PLN-101095 plus pembrolizumab produced one confirmed complete response and three partial responses among ten secondary ICI-refractory patients, with 60% showing stable disease or tumor reduction. Pliant plans a Phase 1b indication-expansion trial in non-small cell lung cancer and other tumor types in 2026.
The company built a proprietary library of over 15,000 integrin-binding molecules supporting early programs, including siRNA delivery to specific cell types. Pliant discontinued development of bexotegrast in idiopathic pulmonary fibrosis after a Phase 2b safety imbalance, and currently sees no cost-effective path forward in primary sclerosing cholangitis.
Pliant Therapeutics has extended its stockholder rights plan by one year. The company and Computershare Trust Company, N.A., amended their Stockholder Rights Agreement so that the associated rights now expire at 5:00 p.m. New York City time on March 11, 2027, instead of March 11, 2026.
The plan is intended to make it harder for any person, entity or group to gain control of the company through open market share purchases without paying all stockholders an appropriate control premium or giving the board enough time to evaluate alternatives. The company states the change was not made in response to any specific takeover offer and is not meant to block mergers or other business combinations approved by the board.
Pliant Therapeutics, Inc. received an amended Schedule 13G/A from Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reporting a small ownership position. As of the close of business on December 31, 2025, the group beneficially owned 46,537 shares of common stock, representing 0.1% of the outstanding class.
The filing explains that the shares are held by an investment fund managed by Point72 Asset Management, with Point72 Capital Advisors as its general partner and Mr. Cohen controlling both entities. The filers state that the securities were not acquired and are not held for the purpose of changing or influencing control of Pliant Therapeutics.
Woodline Partners LP filed an amended Schedule 13G/A reporting its beneficial ownership of Pliant Therapeutics common stock. Woodline reports beneficial ownership of 2,026,191 shares, representing 3.3% of the outstanding common stock, based on 61,449,385 shares outstanding as of November 1, 2025.
The shares are held through Woodline Master Fund LP, for which Woodline Partners serves as investment adviser, with sole voting and dispositive power over all reported shares. Woodline certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Pliant Therapeutics.
Kenneth Griffin and affiliated Citadel entities report a 5.0% beneficial ownership stake in Pliant Therapeutics, Inc. common stock. The group may be deemed to beneficially own 3,042,133 Shares, based on 61,449,385 Shares outstanding as of November 1, 2025.
Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 2,099,798 Shares, while Citadel Securities LLC may be deemed to own 913,609 Shares. All reporting persons have shared, but not sole, voting and dispositive power over their respective positions and certify the holdings are not for the purpose of changing or influencing control of Pliant.
Citadel-affiliated entities and Kenneth Griffin report a significant but sub-5% passive stake in Pliant Therapeutics, Inc. They collectively may be deemed to beneficially own 3,037,695 common shares, equal to 4.9% of the company’s stock, based on 61,449,385 shares outstanding as of November 1, 2025.
The shares are held through Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and related vehicles. All voting and dispositive powers are shared, and the reporting persons certify the holdings were not acquired to change or influence control of Pliant.
Pliant Therapeutics reported that its Chief Financial Officer, Keith Lamont Cummings, received a new stock option grant. The option allows him to buy 400,000 shares of common stock at an exercise price of $1.30 per share, expiring on January 22, 2036. According to the vesting terms, 1/48th of the shares vest and become exercisable on each monthly anniversary of January 1, 2026, as long as he continues to serve the company. After this award, he holds 400,000 stock options directly.
Pliant Therapeutics, Inc. reported that its Chief Operating Officer, Minnie Kuo, received a stock option grant for 300,000 shares of common stock. The option has an exercise price of $1.30 per share and was granted on January 22, 2026, with an expiration date of January 22, 2036. No purchase price was paid for the grant itself.
According to the vesting terms, 1/48th of the option vests and becomes exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, as long as Kuo continues to provide service to the company on each vesting date. After vesting, the option allows her to buy Pliant common shares at the fixed exercise price within the option term.
Pliant Therapeutics granted its Chief Human Resource Officer, Lily Cheung, a stock option on January 22, 2026. The option gives her the right to buy 300,000 shares of common stock at an exercise price of $1.30 per share, expiring on January 22, 2036.
According to the vesting terms, 1/48th of the option vests in substantially equal monthly installments on each monthly anniversary of January 1, 2026, as long as she continues serving the company. After this grant, she directly holds 300,000 stock options.
Pliant Therapeutics President and CEO Bernard Coulie received a grant of stock options covering 1,230,000 shares of common stock on January 22, 2026. The options have an exercise price of $1.30 per share and are held directly. According to the vesting terms, 1/48th of the shares subject to the option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, contingent on his continued service with the company.